Table 1.
Clinical characteristics of patients with eosinophilic oesophagitis and of control patients
| Patient no. | Age (years)/Gender | Eosinophil peak/hpf | Total IgE (ng/ml) | Asthma | Allergic rhinitis | Eczema | Therapy |
| Eosinophilic oesophagitis (n = 11) | |||||||
| 1 | 6/M | 35 | NA | + | + | − | β2-Agonist, antihistaminic |
| 2 | 10/M | 85 | 148 | − | + | − | PPI, antihistaminic |
| 3 | 7/M | 50 | 20 | NA | + | − | Antibiotic |
| 4 | 7/M | 82 | NA | + | + | + | PPI, β2-agonist, antihistaminic |
| 5 | 13/F | 91 | 1590 | + | + | + | PPI, β2-agonist, antihistaminic |
| 6 | 4/F | 28 | 420 | − | − | + | β2-Agonist, antihistaminic |
| 7 | 6/F | 71 | NA | − | + | − | PPI, antihistaminic |
| 8 | 16/M | 24 | 316 | − | − | − | None |
| 9 | 14/M | 76 | NA | − | − | − | PPI, LTRA |
| 10 | 3/M | 68 | 17 | − | − | − | PPI |
| 11 | 2/M | 51 | 347 | − | − | − | PPI |
| Controls (n = 8) | |||||||
| 12 | 2/M | 0 | 216 | + | + | − | Antibiotic |
| 13 | 16/F | 0 | 402 | + | + | − | PPI |
| 14 | 2/M | 5 | 5 | − | + | − | PPI, antihistaminic |
| 15 | 2/M | 2 | 16 | − | + | + | PPI |
| 16 | 8/M | 0 | NA | + | + | NA | PPI |
| 17 | 7/M | 2 | NA | − | − | − | PPI, β2-agonist |
| 18 | 8/M | 3 | NA | − | − | − | None |
| 19 | 6/M | 0 | 5 | − | − | − | PPI, antihistaminic |
Serum IgE concentration in control individuals was 96 ng/ml.34
F, female; hpf, high-power, field; IgE, immunoglobulin E; LTRA, leukotriene receptor antagonist; M, male; NA, not available; PPI, proton pump inhibitor.